Security
Lakewood-Amedex Biotherapeutics Inc. Common Stock · LABT
LABTNASDAQCommon stockCurrentCIK 2079272Updated Oct 6, 2026
LABT price & chart
Loading TradingView…
NASDAQ:LABT on TradingView ↗About the company
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms.
In the news
Recent filings
Offerings
Registration 333-299027
Registration 333-295497
- Offering price
- market-price
- Ticker
- LABT
Registration 333-292664
- Offering price
- market-price
- Ticker
- LABT
Underwriters: Dawson James Securities, Inc.
Filing attachments
ea029796301ex99-1.htm · 8-K · 2026-07-15
EX-99.1 2 ea029796301ex99-1.htm LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC., INVESTOR DECK, DATED JULY 15, 2026 Exhibit 99.1 Pioneering Bisphosphocin® Compounds Advancing a novel class of fast- acting antimicrobials toaddress the global threat ofresistance 1 Forward-looking Statements This presentation may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intends," "estimate," "anticipate," "project," …
Read attachment ↗ea028796001ex99-1.htm · 8-K · 2026-04-28
EX-99.1 4 ea028796001ex99-1.htm PRESS RELEASE DATED APRIL 28, 2026 Exhibit 99.1 Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph. D., to Board of Directors Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 - Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for inf…
Read attachment ↗ea024866805ex99-1_lakewood.htm · S-1 · 2026-01-09
Exhibit 99.1 LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. GOVERNANCE AND NOMINATING COMMITTEE CHARTER I. PURPOSE The Governance and Nominating Committee (the “Committee”) is appointed by the Board of Directors (the “Board”): (1) to assist the Board by identifying qualified candidates for director, and to recommend to the Board the director nominees for the next annual meeting of shareholders; (2) to lead the Board in its annual review of the Board’s performance; (3) to recommend to the Board director…
Read attachment ↗ea024866805ex99-2_lakewood.htm · S-1 · 2026-01-09
Exhibit 99.2 LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. COMPENSATION COMMITTEE CHARTER PURPOSE The purpose of the Compensation Committee (the “CC”) of the Board of Directors of Lakewood-Amedex Biotherapeutics Inc., (the “Company”) is: 1. To discharge the responsibilities of the Board of Directors (the “BOD”) of the Company relating to compensation of the Company’s directors, executive officers and key employees; 2. To assist the BOD in establishing appropriate incentive compensation and equity-…
Read attachment ↗